Induction of Apoptosis in HeLa by Corn Small RNAs.

Insights in RNA biology have opened up a plethora of opportunities to explore the small regulatory RNAs from various natural and artificial sources. These small RNAs have been suggested to play a role too in tumor progression by either as oncogenic or tumor suppressor small RNAs. In this study, authors have attempted to evaluate the therapeutic potential of small RNAs fractionated from corn (Zea mays) upon growth and survival of HeLa. Here, authors have employed standard cellular-based approaches including microscopy, spectroscopy, and flow cytometry-based staining assays. Our data indicate that corn small RNAs fraction can appreciably decrease HeLa cell proliferation and survival, which is supported by a number of complementary assays such as Trypan blue dye exclusion, MTT, propidium iodide, and Annexin V/PI apoptotic cell death. Taken together, present finding suggests that corn small RNAs fraction may display up to 70% reduction in HeLa cell viability. Furthermore, these data indicate that around 40-50% of HeLa cells become apoptotic due to exogenous use of corn small. Overall, this finding proposes that possibility of cross-kingdom anticancer use of small RNAs from corn and present data need to be explored in depth.

Induction of S-phase Cell Cycle Arrest and Apoptosis in HeLa Cells by Small RNAs Fraction of Solanum tuberosum L.

BACKGROUND: In cancer therapeutics, several new classes of small molecules based targeted drug options are reported including peptide mimetic and small RNAs therapeutics. OBJECTIVE: Small RNAs represent a class of short non-coding endogenous RNAs that play an important role in transcriptional and post transcriptional gene regulation among varied types of species including plants and animals. METHODS: To address the role of small RNAs from plant sources upon cancer cells, authors report on the effects of small RNAs fraction of potato in in-vitro model of human derived HeLa cancer cells. This paper reports the anti-proliferative and anti-survival effect of small RNAs fraction of S. tuberosum L. (potato) tuber tissue. Here, authors employed small RNAs fractionation protocol, cell viability, cell cytotoxicity MTT, PI stained cell cycle analysis and FITC-Annexin-V/PI stained apoptosis assays. RESULTS: In this paper, small RNAs fractions of potato clearly indicate 40-50% inhibition of HeLa cell proliferation and viability. Interestingly, flow cytometer data point out appreciable increase from 7% to 14% of S-phase in HeLa cells by displaying the presence of an S-phase cell cycle arrest. Further, arrest in S-phase of HeLa cells is also supported by an appreciable increase in total <2N plus >4N DNA containing HeLa cells over 2N containing HeLa cells. For apoptotic assay, data suggest a significant increase in apoptotic HeLa cells from (5%) control treated HeLa cells to (18%) small RNAs treated HeLa cells. CONCLUSION: Taken together, findings suggest that small RNAs fractions of potato can induce Sphase cell cycle arrest and these agents can act as an anti-proliferative agent in HeLa cells. This paper proposes a huge scope for novel finding to dissect out the small RNAs target within HeLa cells and other cancer cell types.

Natural and artificial small RNAs: a promising avenue of nucleic acid therapeutics for cancer.

Since the failure of traditional therapy, gene therapy using functional DNA sequence and small RNA/DNA molecules (oligonucleotide) has become a promising avenue for cancer treatment. The discovery of RNA molecules has impelled researchers to investigate small regulatory RNA from various natural and artificial sources and determine a cogent target for controlling tumor progression. Small regulatory RNAs are used for therapeutic silencing of oncogenes and aberrant DNA repair response genes. Despite their advantages, therapies based on small RNAs exhibit limitations in terms of stability of therapeutic drugs, precision-based delivery in tissues, precision-based intercellular and intracellular targeting, and tumor heterogeneity-based responses. In this study, we summarize the potential and drawbacks of small RNAs in nucleic acid therapeutics for cancer.